Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 6;15(4):1032.
doi: 10.3390/cancers15041032.

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study

Valentina Tuninetti  1 , Eleonora Ghisoni  2 , Sandro Pignata  3 , Elisa Picardo  4 , Francesco Raspagliesi  5 , Claudia Andreetta  6 , Elena Maldi  7 , Grazia Artioli  8 , Serafina Mammoliti  9 , Lucia Zanchi  10 , Angelica Sikokis  11 , Nicoletta Biglia  12 , Alessandro Parisi  13   14 , Vincenzo Dario Mandato  15 , Claudia Carella  16 , Gennaro Cormio  17   18 , Marco Marinaccio  19 , Andrea Puppo  20 , Biagio Paolini  21 , Lucia Borsotti  22 , Giulia Scotto  23 , Margherita Turinetto  23 , Dario Sangiolo  23 , Massimo Di Maio  1 , Giorgio Valabrega  1
Affiliations

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study

Valentina Tuninetti et al. Cancers (Basel). .

Abstract

Background: There is compelling need for novel biomarkers to predict response to PARP inhibitors (PARPi) in BRCA wild-type (WT) ovarian cancer (OC).

Methods: MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment and PARPi maintenance. Clinical data were collected from high grade serous or endometroid BRCAWT OC treated with niraparib or rucaparib maintenance between 2010-2021 in 15 centers. Ki67 expression was assessed locally by certified pathologists on formalin-fixed paraffin embedded (FFPE) tissues. Median Ki67 was used as a cut-off.

Results: A total of 136 patients were eligible and included in the analysis. Median Ki67 was 45.7% (range 1.0-99.9). The best response to platinum according to median Ki67 was 26.5% vs. 39.7% complete response (CR), 69.1% vs. 58.8% partial response (PR), 4.4% vs. 1.5% stable disease (SD). The best response to PARPi according to median Ki67 was 19.1% vs. 36.8% CR, 26.5% vs. 26.5% PR, 26.5 vs. 25% SD, 27.9% vs. 16.2% progressive disease (PD). No statistically significant differences in progression free survival (PFS) and overall survival (OS) were identified between low and high Ki67. PFS and OS are in line with registration trials.

Conclusions: Ki67 at diagnosis did not discriminate responders to PARPi.

Keywords: Ki67; PARP inhibitor; niraparib; ovarian cancer; rucaparib.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Ki67 IHC staining on ovarian cancer tissue. Original magnification 200×. (A) high Ki67 (>45.7%). (B) low Ki67 (<45.7%).
Figure 2
Figure 2
Flowchart of the study.
Figure 3
Figure 3
Progression-free survival (PFS) according to the median Ki67 value.
Figure 4
Figure 4
Overall survival (OS) according to the median Ki67 value.
See this image and copyright information in PMC

References

    1. Poveda A.M., Selle F., Hilpert F., Reuss A., Savarese A., Vergote I., Witteveen P., Bamias A., Scotto N., Mitchell L., et al. Bevacizumab Combined with Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. J. Clin. Oncol. 2015;33:3836–3838. doi: 10.1200/JCO.2015.63.1408. - DOI - PubMed
    1. Penson R.T., Valencia R.V., Cibula D., Colombo N., Leath C.A., Bidziński M., Kim J.W., Nam J.H., Madry R., Hernández C., et al. Olaparib versus Nonplatinum Chemotherapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J. Clin. Oncol. 2020;38:1164–1174. doi: 10.1200/JCO.19.02745. - DOI - PMC - PubMed
    1. Moore K., Colombo N., Scambia G., Kim B.G., Oaknin A., Friedlander M., Lisyanskaya A., Floquet A., Leary A., Sonke G.S., et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 2018;379:2495–2505. doi: 10.1056/NEJMoa1810858. - DOI - PubMed
    1. Halverson J.L., Martinez-Donate A.P., Palta M., Leal T., Lubner S., Walsh M.C., Strickland J.S., Smith P.D., Trentham-Dietz A. Health Literacy and Health-Related Quality of Life Among a Population-Based Sample of Cancer Patients. J. Health Commun. 2015;20:1320–1329. doi: 10.1080/10810730.2015.1018638. - DOI - PMC - PubMed
    1. González-Martín A., Pothuri B., Vergote I., DePont Christensen R., Graybill W., Mirza M.R., McCormick C., Lorusso D., Hoskins P., Freyer G., et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 2019;381:2391–2402. doi: 10.1056/NEJMoa1910962. - DOI - PubMed